The following articles have showcased
Absynth Biologics (please note that we are not responsible for the content of
external websites).
Absynth receives £100,000 funding from Yorkshire Forward. December 2008. For more information see Absynth
News.
BBSRC Leaflet. Jan 2008. Issue: Tackling ‘Superbugs’.
New companies take up the fight. Absynth Biologics. p. 14. “… a unique
group of surface-exposed proteins of S. aureus … are good novel targets
for a vaccine and for prophylactic or therapeutic antibodies control of
infection … The research findings are being taken towards clinical
application by ABsynth Biologics.”
BBSRC business. Jul 2007. Spin out sets to
tackle MRSA. p. 12. “Through underpinning BBSRC-funded research we have
identified a unique pool of immunological targets, with esential roles in
cellular physiology and pathogenicity … Absynth Biologics gives an
exciting opportunity to translate our basic research into real clinical
application”
Helix - Bioscience cluster news from Yorkshire Forward.
May 2007. Issue 07. ABsynth Biologics: Spin out company battles superbug.
p. 2. “The concept (Absynth Biologics) uses an immunological approach to
target a novel set of proteins ... important for the growth and/or
pathogenesis of the bacterium …”
